BVS - Bioventus enrolls first patient in early-stage MOTYS osteoarthritis trial

Bioventus (BVS) reported that the first patients have been enrolled and dosed in its Phase 1 open-label, dose-escalation study evaluating the safety and efficacy of MOTYS ((PTP-001)) to treat osteoarthritis ((OA)) of the knee.Current treatments for knee OA are limited to corticosteroids and hyaluronic acid ((HA)) injections.Patients in the trial will be followed up to evaluate local and systemic reactions to the drug candidate, as well as to assess any improvements in pain and mobility over the course of this clinical study.MOTYS is a placental tissue particulate comprised of amnion, chorion and umbilical cord tissue from full-term, healthy births and is provided sterile in micronized form.

For further details see:

Bioventus enrolls first patient in early-stage MOTYS osteoarthritis trial